C. H. Pui and W. E. Evans, Treatment of acute lymphoblastic leukemia, N Engl J Med, vol.54, pp.166-78, 2006.

G. Comi, Induction vs. escalating therapy in multiple sclerosis: practical implications, Neurol Sci, vol.29, pp.253-258, 2008.

P. Reickmann, Concepts of induction and escalation therapy in multiple sclerosis, Neurol Sci, vol.277, pp.42-47, 2009.

G. Edan, L. Page, and E. , Induction therapy for patients with multiple sclerosis: why? When? How?, CNS Drugs, vol.27, issue.6, pp.403-412, 2013.
DOI : 10.1007/s40263-013-0065-y
URL : https://hal.archives-ouvertes.fr/hal-00877114

H. Wiendl, Cladribine-an old newcomer for pulsed immune reconstitution in MS, Nat Rev Neurol, vol.13, issue.10, pp.573-577, 2017.
DOI : 10.1038/nrneurol.2017.119

E. Leray, J. Yaouanq, L. Page, E. Coustans, M. Laplaud et al., Evidence of a two stage disability progression in multiple sclerosis, Brain, vol.133, pp.1900-1913, 2010.

A. Scalfari, A. Neuhaus, and A. Degenhardt, The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability, Brain, vol.133, pp.1914-1943, 2010.

L. K. Fisniku, P. A. Brex, and D. R. Altmann, Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, vol.131, pp.808-825, 2008.

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-or et al., Ocrelizumab versus placebo in primary progressive multiple sclerosis, N Engl J Med, vol.376, issue.3, pp.209-229, 2016.
DOI : 10.1056/nejmoa1606468
URL : https://hal.archives-ouvertes.fr/hal-01793440

B. Z. Chaudhry, J. A. Cohen, and D. S. Conway, Sphingosine 1phosphate receptor modulators for the treatment of multiple sclerosis, Neurotherapeutics, vol.14, issue.4, pp.859-73, 2017.

H. L. Weiner, The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease, Ann Neurol, vol.65, pp.239-287, 2009.
DOI : 10.1002/ana.21640
URL : http://onlinelibrary.wiley.com/doi/10.1002/ana.21640/pdf

M. P. Sormani, C. Gasperini, M. Romeo, J. Rio, M. Calabrese et al., Assessing response to interferon-b in a multicenter dataset of patients with MS, Neurology, vol.87, issue.2, pp.134-174, 2016.

G. Edan, D. Miller, and M. Clanet, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry, vol.62, pp.112-120, 1997.

L. Page, E. Leray, E. Taurin, G. Coustans, M. Chaperon et al., Mitoxantrone as induction treatment in aggressive relapsing-remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry, vol.79, pp.52-58, 2008.

G. Edan, C. Comi, L. Page, E. Leray, E. Rocca et al., Mitoxantrone prior to interferon-beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial, J Neurol Neurosurg Psychiatry, vol.82, pp.1344-50, 2011.
DOI : 10.1136/jnnp.2010.229724

L. Page, E. Leray, E. Edan, and G. , Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study, Mult Scler, vol.17, issue.7, pp.867-75, 2011.

T. Vollmer, H. Panitch, and A. Bar-or, Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis, Mult Scler, vol.00, pp.1-8, 2008.
DOI : 10.1177/1352458507085759

, Alemtuzumab vs. interferon-beta-1a in early multiple sclerosis, The CAMMS223 Trial Investigators, vol.359, pp.1786-801, 2008.

J. A. Cohen, A. J. Coles, and D. L. Arnold, Alemtuzumab versus interferon-beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial, Lancet, vol.380, issue.9856, pp.1819-1847, 2012.

A. J. Coles, C. L. Twyman, and D. L. Arnold, Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: a randomised phase 3 trial, Lancet, vol.380, issue.9856, pp.1829-1868, 2012.

A. J. Coles, E. Fox, and A. Vladic, Alemtuzumab more effective than interferon b-1a at 5-year follow-up of CAMMS223 clinical trial, Neurology, vol.78, issue.14, pp.1069-78, 2012.

G. Giovannoni, G. Comi, and S. Cook, A placebo controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, vol.362, pp.416-442, 2010.

G. Giovannoni, S. Sorensen, P. Cook, S. Rammohan, K. Rieckmann et al., Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study, Mult Scler, 2017.

D. H. Miller, O. A. Khan, W. A. Sheremata, L. D. Blumhardt, G. Rice et al., A controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.348, pp.15-23, 2003.

A. Kerbrat, L. Page, E. Leray, and E. , Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing-remitting multiple sclerosis patients, J Neurol Sci, vol.308, issue.1-2, pp.98-102, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01147033

L. Ferrè, L. Moiola, F. Sangalli, M. Radaelli, V. Barcella et al., Recurrence of disease activity after repeated natalizumab withdrawals, Neurol Sci, vol.36, issue.3, pp.465-472, 2014.

S. L. Hauser, A. Bar-or, G. Comi, G. Giovannoni, H. Hartung et al., Ocrelizumab versus interferon-beta-1a in relapsing multiple sclerosis, N Engl J Med, vol.376, issue.3, pp.221-255, 2017.

D. S. Alberts, Y. M. Peng, and G. T. Bowden, Pharmacology of mitoxantrone: mode of action and pharmacokinetics, Invest New Drugs, vol.3, pp.101-108, 1985.

D. Faulds, J. A. Balfour, P. Chrisp, and H. D. Langtry, Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer, Drugs, vol.41, pp.400-99, 1991.

H. Lenk, U. Mü-ller, and S. Tanneberger, Mitoxantrone: mechanisms of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity, Anticancer Res, vol.7, pp.1257-64, 1987.

J. Koeller and M. Eble, Mitoxantrone: a novel anthracycline derivative, Clin Pharm, vol.7, pp.574-81, 1998.

T. D. Shenkenberg, V. Hoff, and D. , Mitoxantrone: a new anticancer drug with significant clinical activity, Ann Intern Med, vol.105, pp.67-81, 1986.

B. S. Wang, K. C. Murdock, and A. L. Lumanglas, Relationship of chemical structures of anthraquinones with their effects on the suppression of immune responses, Int J Immunopharm, vol.9, pp.733-742, 1987.

B. S. Wang, A. L. Lumaglas, and V. M. Ruszala-mallon, aminoethyl)amino]-5,8-dihydroxy-9,10-anthracenedione dihydrochloride (CL 232,468), Int J Immunopharmacol, vol.1, issue.2, pp.475-82, 1984.
DOI : 10.1016/0192-0561(84)90086-9

J. Greenwood, S. D. Gorman, E. G. Routledge, I. S. Lloyd, and H. Waldmann, Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis, Ther Immunol, vol.1, pp.247-55, 1994.

A. J. Coles, M. Wing, and P. Molyneux, Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis, Ann Neurol, vol.46, pp.296-304, 1999.

A. J. Coles, A. Cox, L. Page, and E. , The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, vol.253, pp.98-108, 2006.

A. J. Coles, J. A. Cohen, E. J. Fox, G. Giovannoni, H. P. Hartung et al., Alemtuzumab CARE-MS II 5-year followup: efficacy and safety findings, Neurology, vol.89, issue.11, pp.1117-1143, 2017.

T. Ziemssen and K. Thomas, Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world, Ther Adv Neurol Disord, vol.10, issue.10, pp.343-59, 2017.